Monash University-led research is using ticks to help unlock better ways to fight inflammation, which causes considerable suffering in people globally.
The Monash Biomedicine Discovery Institute-led team has ‘hijacked’ an anti-inflammatory mechanism used by ticks to block the activity of proteins important in human inflammatory diseases.
Chronic inflammatory diseases like atherosclerosis, pulmonary fibrosis, rheumatoid arthritis and cancers cause much suffering worldwide.
The associated inflammation is caused by the release of proteins called chemokines in the affected tissues, so researchers are seeking ways to block the activity of chemokines.
Conducted by PhD student Shankar Devkota and published in Nature Communications, this study discovered a new family of tick salivary proteins called A3 evasins.
These evasins can block numerous chemokines, suggesting they could be repurposed to target chemokines involved in human inflammatory diseases.
By analysing the 3D structures of these evasins and their interactions with chemokines, the team designed and engineered evasin variants that inhibit chemokines involved in atherosclerosis and rheumatoid arthritis.
Co-senior Author Dr Ram Bhusal, of the Monash Biomedicine Discovery Institute, said this proof-of-principle study laid a foundation for the future development of engineered evasins that could be used to develop improved inflammation treatments.
“It turns out that ticks have naturally evolved the ability to block chemokine-driven inflammation, which enables them to live on their hosts for extended periods without the host being aware of them,” he said.
Dr Bhusal said the tick evasins were special because no current anti-inflammatory drugs were designed to target chemokines directly.
“The tick-derived evasins represent a novel class of anti-inflammatory agents with a distinct mode of action to inhibit chemokines,” he said. “As such, they offer a fresh perspective and an alternative strategy for reducing inflammation in the body.”
Co-senior author Professor Martin Stone said more research and human trials were needed, but the development was promising.
“This finding is significant because it opens up possibilities for developing a new generation of anti-inflammatory drugs,” he said. “These new drugs could improve the treatment options for patients with chronic inflammatory diseases, potentially saving lives and reducing suffering.”
Read the full paper in Nature Communications: Engineering broad-spectrum inhibitors of inflammatory chemokines from subclass A3 tick evasins.
This research was largely funded by the National Health and Medical Research Council (NHMRC) and Monash University. The work was conducted in collaboration with the ARC Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS).
DOI: 10.1038/s41467-023-39879-3
For media enquiries please contact:
Monash University
Cheryl Critchley - Communications Manager (medical)
E: cheryl.critchley@monash.edu
T: +61 (0) 418 312 596
For more Monash media stories, visit our news and events site
For general media enquiries please contact:
Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840
About the Monash Biomedicine Discovery Institute
Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
